CFRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (5 Dec 2023 @ 15:31):

Stats
Today's Volume	910 216
Average Volume	262 784
Market Cap	371 901
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.00462
ATR14	$0.0290 (82.98%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-14	Messinger Michael	Buy	25 000	Options (Right to Buy)
2022-05-17	Barlow Jane F	Buy	42 000	Options (Right to Buy)
2022-05-17	Sucoff Cary	Buy	42 000	Options (Right to Buy)
2022-05-17	Otto Michael J.	Buy	42 000	Options (Right to Buy)
2022-05-17	Low David N.	Buy	42 000	Options (Right to Buy)

INSIDER POWER
100.00
Last 55 transactions
Buy: 2 642 000 \| Sell: 9 700 000

Volume Correlation

Long: -0.02 (neutral)

Short: -0.53 (weak negative)

Signal:(32.31) Neutral

ContraFect Corp Correlation

10 Most Positive Correlations
ENNV	0.961
EVLO	0.96
CLFD	0.952
ALXO	0.951
YJ	0.95
NAKD	0.949
SLNG	0.946
GXGX	0.946
REYN	0.945
BHTG	0.943

10 Most Negative Correlations
TIOAU	-0.973
VLAT	-0.97
LGVC	-0.97
PRLH	-0.967
FICV	-0.966
TIOA	-0.964
SCRM	-0.963
IVCP	-0.962
INTA	-0.962
LDHA	-0.961

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ContraFect Corp Correlation - Currency/Commodity

-0.90
( strong negative )

-0.91
( very strong negative )

0.00
( neutral )

-0.58
( weak negative )

0.03
( neutral )

-0.08
( neutral )

ContraFect Corp Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-126.01

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.500

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.940

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$3.10

Financial Reports:

No articles found.

ContraFect Corp

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.